mTOR Inhibitors Therapeutics Pipeline - Analysis, Clinical Trials, Collaborations and Developments

According to the research findings, most of the drug candidates that act as mTOR inhibitors are being developed as small molecules, further supported by the fact that small molecules have several advantages such as it can be manufactured with production rate higher than any other molecule types.

Explore report sample at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-therapeutics/report-sample

The positive clinical results of mTOR inhibitors drug candidates is a key factor driving the pipeline growth. For instance, F. Hoffman-La-Roche AG has developed a drug candidate, ipatasertib, that acts as mTOR inhibitors. The Phase II clinical results (Study ID: NCT02162719) of the drug candidate were published in the Lancet Oncology journal. It has been observed that progression-free survival was longer in patients who received ipatasertib as compared in those who received placebo.

Most of the companies are developing innovative technologies for the synthesis or production of mTOR inhibitors. For instance, PHusis Therapeutics Inc. is using its computational modeling platform namely, PHuDock, that identify inhibitors of proteins which promotes the growth of cancer cells. Using PHuDock, X-ray structural information and surface plasmon resonance spectroscopic measurements of selected drug-like molecules, PHusis is rapidly and efficiently identifying agents involving toxicity studies, that selectively inhibit the activity of a number of these cancers driving proteins. PHuDock is applied to lead identification and optimization, as well as to predict the compounds off-target properties and toxicity, therefore delivering novel and highly effective agents with low toxicity.

Browse report at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-therapeutics

These technologically advanced platforms enable the players in the pipeline to develop effective new therapies rapidly, that are cost effective and potentially have lower risk of toxicity, and relative to traditional approaches. Thus, these technological advancements act as a key driver for the pipeline growth.

Some of the key players involved in the development of mTOR inhibitors therapeutics include F. Hoffman-La-Roche AG, Pfizer Inc., and resTORbio Inc.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.